Cardiovascular pharmacogenomics is a cutting-edge field that explores the intersection of genetics and cardiovascular medicine. It focuses on how an individual's genetic makeup influences their response to cardiovascular drugs, aiming to optimize treatment outcomes and minimize adverse effects. By studying the genetic variations that affect drug metabolism, efficacy, and toxicity, researchers in cardiovascular pharmacogenomics seek to tailor medication regimens to each patient's unique genetic profile. This personalized approach holds the potential to enhance the effectiveness of cardiovascular therapies, reduce the likelihood of side effects, and improve overall patient outcomes. As our understanding of the human genome continues to advance, cardiovascular pharmacogenomics promises to play a crucial role in the evolution of precision medicine, bringing us closer to more individualized and targeted treatments for cardiovascular diseases.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation